Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed h...
Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed high-risk lymphoma ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
Glofitamab induces durable complete remissions in patients with relapsed large B...
Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )
13 Jun 2022
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy i...
Prof Barbara Eichhorst - University of Cologne, Cologne, Germany
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )
13 Jun 2022
Quizartinib advances overall survival in acute myeloid leukaemia patients
Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA
Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )
13 Jun 2022
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for ...
Dr Elias K. Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients ( Dr Elias K. Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodg...
Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )
13 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )
9 Jun 2022
Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...
Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022